Thymic humoral factor-γ2 (THF-γ2) immunotherapy reduces the metastatic load and restores immunocompetence in 3LL tumor-bearing mice receiving anticancer chemotherapy

Immunopharmacology and Immunotoxicology

Volumn 18, Issue 2, 1996, Pages 209-236

  Ophir, Rachel ^a   Pecht, Marit ^b   Keisari, Yona ^a   Rashid, Gloria ^a   Lourie, Sylvie ^b   Meshorer, Asher ^b   Ben Efraim, Shlomo ^a   Trainin, Nathan ^b   Burstein, Yigal ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; HUMORAL THYMUS FACTOR; MELPHALAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; COLONY FORMING UNIT GM; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; LUNG CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA;

EID: 0029893504     PISSN: 08923973     EISSN: None     Source Type: Journal    
DOI: 10.3109/08923979609052733     Document Type: Article

References (30)

1. Burstein, Y., Buchner, V., Pecht, M., Trainin, N., THF-γ2: purification and amino acid sequence of an immunoregulatory peptide from calf thymus, Biochemistry, 27:4066, 1988.
2. Trainin, N., Handzel, Z.T., Pecht, M., Biological and clinical properties of THF, Thymus, 7:137, 1985.
3. Trainin, N., Pecht, M., Burstein, Y., Thymic humoral factor THF-γ2: an immunoregulatory octapeptide, in Frontiers in cancer research, edited by A. Frensdorff, p. 263, Ramot Publishing, Tel-Aviv University, Tel-Aviv, 1994.
4. Trainin, N., Prospects of AIDS therapy by thymic humoral factor, a thymic hormone, Natural immunity and cell growth regulation, 9:155, 1990.
5. Goso, C., Frasca, D., Doria, G., Effect of synthetic thymic humoral factor (THF-γ2) on T cell activities in immunodeficient aging mice, Clin. Exp. Immunol., 87:346, 1992.
6. Pecht, M., Lourie, S., Burstein, Y., Zipori, D., Trainin, N., Potentiation of myeloid colony-formation in bone marrow of intact and neonatally thymectomized mice by the thymic hormone THF-γ2, Exp. Hematol., 21:277, 1993.
7. Barak, Y., Hahn, T., Pecht, M., Karov, Y., Berrebi, A., Zaizov, R., Stark, B., Buchner, V., Burstein, Y., Trainin, N., Thymic humoral factor-γ2 , an immunoregulatory peptide, enhances human hematopoietic progenitor cell growth, Exp. Hematol., 20:173, 1992.
8. Trainin, N., Burstein, Y., Ben-Efraim, S., Goebel, F.D., Handzel, Z.T., The use of THF, a thymic hormone, for immunomodulation in cancer and AIDS. In Novel approaches in cancer therapy, edited by K. Lapis and S. Ekhardt, p. 253, Budapest, 1987. (Lectures and symposia of the 14th International Cancer Congress).
9. Handzel, Z.T., Burstein, Y., Buchner, V., Pecht, M., Trainin, N., Immune-modulation of T-cell deficiency in humans by thymic humoral factor: from the crude extract to synthetic THF-γ2, J. Biol. Response Modifiers, 9:269, 1990.
10. Ophir, R., Pecht, M., Halperin, D., Rashid, G., Burstein, Y., Ben-Efraim, S., Trainin, N., THF-γ2, a thymic hormone, increases immunocompetence and survival in 5-Fluorouracil treated mice bearing MOPC-315 plasmacytoma, Cancer Immunol. Immunother., 30:119, 1989.
11. Ophir, R., Pecht, M., Relyveld, E.H., Burstein, Y., Ben-Efraim, S., Trainin N., THF-γ2, a synthetic thymic hormone, increases effectiveness of combined chemotherapy and immunotherapy against RPC-5 murine plasmacytoma, Int. J. Immunopharmac., 19:751, 1990.
12. Ophir, R., Pecht, M., Burstein, Y., Harshemesh, H., Ben-Efraim, S., Trainin, N., Therapeutic effectiveness against MOPC-315 plasmacytoma of low or high doses of the synthetic thymic hormone THF-γ2 in combination with an "immunomodulating'' or a ''non-immunomodulating'' drug, Int. J. Cancer, 48:96, 1991.
13. Ophir, R., Pecht, M., Rashid, G., Halperin, D., Lourie, S., Burstein, Y., Ben-Efraim, S., Trainin, N., A synthetic thymic hormone,THF-γ2, repairs immunodeficiency of mice cured from plasmacytoma by Melphalan, Int. J. Cancer, 45:1190, 1990.
14. Fraumeni, J.F., Devesa, S.S., Hoover, R.N., Kinlien, L.J., Epidemiology of cancer. In Cancer - principles and practice of oncology, edited by V.T. De Vita, S. Hellman and S.A. Rozenberg, p. 150, Lippincott J.R. Co., Philadelphia, 1993.
15. Fidler, I.J., Balch, C.M., The biology of cancer metastasis and implications for therapy, Curr. Prob. Surg., 24:137, 1987.
16. Sugiura, K., Stock, C.C., Studies in a tumor spectrum. III. The effect of phosphoramides on the growth of a variety of mouse and rat tumors, Cancer Res., 15:38, 1955.
17. Glaves, D., Host defense and metastatic potential, Proc. Am. Ass. Cancer Res., 23:279, 1982.
18. Isakov, N., Katzav, S., Feldman, M., Segal, S., Loss of expression of transplantation antigens encoded by the H-2K locus of Lewis lung carcinoma cells and its relevance to the tumor's metastatic properties, J. Natl. Cancer Inst., 71:139, 1983.
19. Snodgrass, M.J., Moraha, P.S., Kaplan, A.M., Histopathology of the host response to Lewis lung carcinoma: modulation by pyran, J. Natl. Cancer Inst., 55:455, 1975.
20. Eipert, E.F., Adoring L., Couderc, J., A miniaturized in vitro diffusion culture system, J. Immunol. Meth., 22:283, 1978.
21. Ben-Efraim, S., Shoval, S., Ophir, R., The difference between 5-Fluorouracil and Melphalan is in their ability to promote antitumor immune response against MOPC-315 plasmacytoma, Cancer Immunol. Immunother., 22:43, 1986.
22. Ben-Efraim, S., Shoval, S., Gal, T., Ophir, R., Classification of anticancer chemotherapeutic drugs according to their immunopotentiating activity, Anticancer Res., 6:801, 1986.
23. Bocian, R.C., Ben-Efraim, S., Dray, S., Mokyr, M.S., Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor, Cancer Immunol. Immunother., 18:41, 1984.
24. Young, M.R.I., Young, M.E., Wright, M.A., Myelopoiesis-associated suppressor-cell activity in mice with Lewis Lung Carcinoma tumors: interferon-γ plus tumor necrosis factor-α synergistically reduce suppressor cell activity, Int. J. Cancer, 46:245, 1990.
25. Rotter, V., Globerson, A., Nakamura, I., Trainin, N., Studies on characterization of the lymphoid target cell for activity of a thymus humoral factor, J. Exp. Med., 138:130, 1973.
26. Lau, C.Y., Yang, E.Y., Goldstein, G., Studies of thymopoietin pentapeptide (TP5) on experimental tumors. I. TP5 relieves immunosuppression in tumor bearing mice, Cell. Immunol., 66:217, 1982.
27. Cupissol, D., Touraine, J.L., Serrou, B., Ability of lymphocytes treated with thymic factor to decrease lung metastasis in tumor bearing mice, Thymus, 3:9, 1981.
28. Mastino, A., Favalli, C., Grelli, S., Rasi, G., Pica, F., Goldstein, A.L., Garaci, E., Combination therapy with thymosin al potentiates the antitumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice, Int. J. Cancer, 50:493, 1992.
29. Garaci, E., Pica, F., Mastino, A., Palamara, A.T., Belardelli, F., Favalli, C., Antitumor effect of thymosin α1/Interleukin-2 or thymosin al / interferon α,β following cyclophosphamide in mice injected with highly metastatic Friend Erythroleukemia cells, J. Immunother., 13:7, 1993.
30. Kaiserlian, D., Savino, W., Dardenne M., Studies of the thymus in mice bearing the Lewis lung carcinoma, II. Modulation of thymic natural killer activity by thymulin (FTS-Zn) and the antimetastatic effect of zinc, Clin. Immunol. Immunopathol., 28:192, 1983.